Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses

Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated patients aged < 70 years, with stage IV or IIIb (not candidates for radiotherapy) non-small cell lung cancer were eligible. Studied dose-...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gridelli, C, Frontini, L, Perrone, F, Gallo, C, Gulisano, M, Cigolari, S, Castiglione, F, Robbiati, S F, Gasparini, G, Ianniello, G P, Farris, A, Locatelli, M C, Felletti, R, Piazza, E
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2000
Témata:
Regular Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363528/
https://ncbi.nlm.nih.gov/pubmed/10952772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2000.1341
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky